There is an observed increase in mTOR expression in the affected and unaffected skin of HS patients, which directly correlates with disease severity. mTOR activation stimulates the secretion of steroids and promotes the adhesion of hair follicles, leading to follicular plugging. Adalimumab treatment has been shown to significantly reduce mTOR1 expression. Study results indicate that anakinra therapy has proven to be safe as an alternative HS treatment for patients, with injection site pain and mild infections being within the drug’s safety profile. Here, MTOR is linked to histiocytic sarcoma.